ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Phathom Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 158.33% and Operating profit at -218.26% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.11
2
With a growth in Net Sales of 439.36%, the company declared Very Positive results in Jun 25
- NET PROFIT(HY) Higher at USD -170.13 MM
- DEBTORS TURNOVER RATIO(HY) Highest at 3.67 times
- RAW MATERIAL COST(Y) Fallen by -7.53% (YoY)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 64.25%, its profits have fallen by -40.2%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 64.25% in the last 1 year, much higher than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Phathom Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Phathom Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Phathom Pharmaceuticals, Inc.
66.29%
0.30
129.73%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
158.33%
EBIT Growth (5y)
-218.26%
EBIT to Interest (avg)
-11.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.19
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.84
EV to EBIT
-3.40
EV to EBITDA
-3.41
EV to Capital Employed
69.92
EV to Sales
11.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2053.61%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
NET PROFIT(HY)
Higher at USD -170.13 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 3.67 times
RAW MATERIAL COST(Y)
Fallen by -7.53% (YoY
NET SALES(Q)
Highest at USD 39.5 MM
OPERATING PROFIT MARGIN(Q)
Highest at -151.26 %
EPS(Q)
Highest at USD -1.05
-3What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -274.69 MM
Here's what is working for Phathom Pharmaceuticals, Inc.
Net Sales
At USD 39.5 MM has Grown at 439.36%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Profit
Higher at USD -170.13 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 3.67 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Highest at USD 39.5 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -151.26 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD -1.05
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -7.53% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Phathom Pharmaceuticals, Inc.
Operating Cash Flow
Lowest at USD -274.69 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
